Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab for Newly Diagnosed Acute Graft Versus Host Disease
NCT05823675Phase 1Unknown
- Start
- May 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of itolizumab in Acute Graft-Versus-Host Disease (aGvHD) (4 arms). Primary endpoint: Treatment Emergent Adverse Events at 85 days. Status: unknown.
02
Drugs
itolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05823675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823675.